The U.S. FDA has officially announced that Eli Lilly's weight-loss drugs, including Mounjaro and Zepbound, are no longer considered in shortage. This development comes as unexpected demand for Mounjaro's single-use vials had previously created supply challenges. The resolution of these supply issues has significant implications for the market, affecting stocks of companies like Hims & Hers Health, which saw a drop in shares following the FDA's announcement. The end of the shortage is expected to influence competition, particularly impacting companies looking to provide alternatives to Lilly's offerings.